BioXcel Therapeutics (BTAI) Misses Q1 EPS by 129c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.50), $1.29 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $168 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Equirus Starts JSW Energy Ltd (JSW:IN) at Long (1)
• Nippon Paint Said To Offer $8.6 Billion For Akzo's Paint Arm - Bloomberg
• Prabhudas Lilladher Reiterates Hold (3) Rating on Avenue Supermarts (DMART:IN)